27439969|t|Distal, not proximal, colonic acetate infusions promote fat oxidation and improve metabolic markers in overweight / obese men
27439969|a|Gut microbial -derived short-chain fatty acids (SCFA) are believed to affect host metabolism and cardiometabolic risk factors. The present study aim was to investigate the effects of proximal and distal colonic infusions with the SCFA acetate on fat oxidation and other metabolic parameters in men. In this randomized, double-blind crossover trial, six overweight / obese men [body mass index (BMI) 25-35 kg/m(2)] underwent two experimental periods: one with distal and one with proximal colonic sodium acetate infusions. A feeding catheter was endoscopically positioned at the beginning of each period and remained in the colon for three consecutive test days, enabling colonic acetate (100 or 180 mmol/l) or placebo infusion during fasting conditions and after an oral glucose load (postprandial). Fat oxidation and energy expenditure were measured using an open-circuit ventilated hood system and blood samples were repeatedly collected for 2 h during fasting and postprandial conditions. Distal colonic 180 mmol/l acetate infusions increased fasting fat oxidation (1.78±0.28 compared with -0.78±0.89 g fat 2 h(-1), P=0.015), fasting peptide YY (PYY, P=0.01) and postprandial glucose and insulin concentrations (P<0.05), and tended to increase fasting plasma acetate (P=0.069) compared with placebo. Distal 100 mmol/l acetate administration tended to decrease fasting tumour necrosis factor-α (TNF-α; P=0.067) compared with placebo. In contrast, proximal colonic acetate infusions showed no effects on substrate metabolism, circulating hormones or inflammatory markers. In conclusion distal colonic acetate infusions affected whole-body substrate metabolism, with a pronounced increase in fasting fat oxidation and plasma PYY. Modulating colonic acetate may be a nutritional target to treat or prevent metabolic disorders.
27439969	0	6	Distal	T082	C0205108
27439969	12	20	proximal	T082	C0205107
27439969	22	29	colonic	T023	C0009368
27439969	30	47	acetate infusions	T061	C0574032
27439969	48	55	promote	T052	C0033414
27439969	56	69	fat oxidation	T070	C1254365
27439969	74	81	improve	T033	C0184511
27439969	82	99	metabolic markers	T130	C0578570
27439969	103	113	overweight	T184	C0497406
27439969	116	121	obese	T047	C0028754
27439969	122	125	men	T098	C0025266
27439969	126	139	Gut microbial	T001	C4018878
27439969	149	172	short-chain fatty acids	T109,T123	C0015691
27439969	174	178	SCFA	T109,T123	C0015691
27439969	203	207	host	T001	C1167395
27439969	208	218	metabolism	T040	C0025519
27439969	223	251	cardiometabolic risk factors	T033	C0035648
27439969	282	293	investigate	T169	C1292732
27439969	298	305	effects	T080	C1280500
27439969	309	317	proximal	T082	C0205107
27439969	322	328	distal	T082	C0205108
27439969	329	336	colonic	T023	C0009368
27439969	337	346	infusions	T061	C0574032
27439969	356	368	SCFA acetate	T109,T123	C0015691
27439969	372	385	fat oxidation	T070	C1254365
27439969	396	405	metabolic	T169	C0311400
27439969	406	416	parameters	T077	C0549193
27439969	420	423	men	T098	C0025266
27439969	433	443	randomized	T062	C0034656
27439969	445	457	double-blind	T062	C0013072
27439969	458	473	crossover trial	T062	C0150097
27439969	479	489	overweight	T184	C0497406
27439969	492	497	obese	T047	C0028754
27439969	498	501	men	T098	C0025266
27439969	503	518	body mass index	T201	C1305855
27439969	520	523	BMI	T201	C1305855
27439969	554	566	experimental	T080	C1517586
27439969	567	574	periods	T079	C1948053
27439969	585	591	distal	T082	C0205108
27439969	605	613	proximal	T082	C0205107
27439969	614	621	colonic	T023	C0009368
27439969	622	646	sodium acetate infusions	T061	C2034525
27439969	650	666	feeding catheter	T074	C2945625
27439969	671	685	endoscopically	T082	C0442418
27439969	686	696	positioned	T082	C0733755
27439969	704	713	beginning	T079	C0439659
27439969	722	728	period	T079	C1948053
27439969	749	754	colon	T023	C0009368
27439969	782	786	days	T079	C0439228
27439969	797	804	colonic	T023	C0009368
27439969	805	812	acetate	T061	C0574032
27439969	836	843	placebo	T122	C1696465
27439969	844	852	infusion	T061	C0574032
27439969	860	867	fasting	T033	C0015663
27439969	868	878	conditions	T080	C0348080
27439969	892	909	oral glucose load	T109,T121,T123	C1955477
27439969	911	923	postprandial	T079	C0376674
27439969	944	962	energy expenditure	T039	C0014272
27439969	968	976	measured	T080	C0444706
27439969	986	1021	open-circuit ventilated hood system	T074	C0025080
27439969	1026	1039	blood samples	T031	C0178913
27439969	1056	1065	collected	T078	C1516695
27439969	1081	1088	fasting	T033	C0015663
27439969	1093	1105	postprandial	T079	C0376674
27439969	1106	1116	conditions	T080	C0348080
27439969	1118	1124	Distal	T082	C0205108
27439969	1125	1132	colonic	T023	C0009368
27439969	1144	1161	acetate infusions	T061	C0574032
27439969	1172	1179	fasting	T033	C0015663
27439969	1180	1193	fat oxidation	T070	C1254365
27439969	1255	1262	fasting	T033	C0015663
27439969	1263	1273	peptide YY	T116,T125	C0070358
27439969	1275	1278	PYY	T116,T125	C0070358
27439969	1292	1304	postprandial	T079	C0376674
27439969	1305	1312	glucose	T109,T121,T123	C0017725
27439969	1317	1324	insulin	T116,T121,T125	C0021641
27439969	1325	1339	concentrations	T081	C1446561
27439969	1364	1372	increase	T169	C0442805
27439969	1373	1380	fasting	T033	C0015663
27439969	1381	1387	plasma	T031	C0032105
27439969	1388	1395	acetate	T109,T121	C0000975
27439969	1406	1414	compared	T052	C1707455
27439969	1420	1427	placebo	T122	C1696465
27439969	1429	1435	Distal	T082	C0205108
27439969	1447	1469	acetate administration	T061	C0574032
27439969	1480	1488	decrease	T081	C0547047
27439969	1489	1496	fasting	T033	C0015663
27439969	1497	1521	tumour necrosis factor-α	T116,T129	C1456820
27439969	1523	1528	TNF-α	T116,T129	C1456820
27439969	1553	1560	placebo	T122	C1696465
27439969	1575	1583	proximal	T082	C0205107
27439969	1584	1591	colonic	T023	C0009368
27439969	1592	1609	acetate infusions	T061	C0574032
27439969	1620	1627	effects	T080	C1280500
27439969	1631	1640	substrate	T167	C3891814
27439969	1641	1651	metabolism	T040	C0025519
27439969	1653	1664	circulating	T169	C0175630
27439969	1665	1673	hormones	T125	C0019932
27439969	1677	1689	inflammatory	T169	C0333348
27439969	1690	1697	markers	T201	C0005516
27439969	1713	1719	distal	T082	C0205108
27439969	1720	1727	colonic	T023	C0009368
27439969	1728	1745	acetate infusions	T061	C0574032
27439969	1755	1765	whole-body	T017	C0444584
27439969	1766	1775	substrate	T167	C3891814
27439969	1776	1786	metabolism	T040	C0025519
27439969	1806	1814	increase	T169	C0442805
27439969	1818	1825	fasting	T033	C0015663
27439969	1826	1839	fat oxidation	T070	C1254365
27439969	1844	1850	plasma	T031	C0032105
27439969	1851	1854	PYY	T116,T125	C0070358
27439969	1856	1866	Modulating	T082	C0443264
27439969	1867	1874	colonic	T023	C0009368
27439969	1875	1882	acetate	T109,T121	C0000975
27439969	1892	1903	nutritional	T080	C1521739
27439969	1904	1910	target	T169	C1521840
27439969	1914	1919	treat	T061	C0087111
27439969	1931	1950	metabolic disorders	T047	C0025517